Summary
Edwards Lifesciences Corporation reported net sales of $4.386 billion for the fiscal year ended December 30, 2020, representing a slight increase of 0.9% compared to 2019. This growth was primarily driven by the Transcatheter Aortic Valve Replacement (TAVR) segment, which saw a 4.4% increase in sales, bolstered by the adoption of the SAPIEN 3 Ultra System. Despite the global COVID-19 pandemic impacting procedure volumes and clinical trial enrollments, the company demonstrated resilience, maintaining operations and supplying its life-saving technologies. The company also settled a significant patent litigation with Abbott in July 2020, incurring a pre-tax charge of $367.9 million. Financially, Edwards Lifesciences maintained a strong balance sheet with total assets of $7.237 billion and total stockholders' equity of $4.574 billion. The company reported diluted earnings per share of $1.30 for 2020, a decrease from $1.64 in 2019, largely due to the aforementioned litigation settlement. Research and development spending increased by 1% to 17% of net sales, reflecting continued investment in innovation, particularly in the transcatheter mitral and tricuspid therapies pipeline. The company's strategic focus on minimally invasive solutions for structural heart disease positions it well for future growth in a dynamic healthcare market.
Financial Highlights
55 data points| Revenue | $4.39B |
| Cost of Revenue | $1.08B |
| Gross Profit | $3.31B |
| R&D Expenses | $760.70M |
| SG&A Expenses | $1.23B |
| Operating Income | $897.60M |
| Interest Expense | $15.80M |
| Net Income | $823.40M |
| EPS (Basic) | $1.32 |
| EPS (Diluted) | $1.30 |
| Shares Outstanding (Basic) | 622.60M |
| Shares Outstanding (Diluted) | 631.90M |
Key Highlights
- 1Net sales for 2020 reached $4.386 billion, a 0.9% increase over 2019, driven by TAVR product sales.
- 2The TAVR segment continues to be the largest contributor to net sales, accounting for 65% of the total.
- 3The company settled significant patent litigation with Abbott for $367.9 million (pre-tax charge), impacting 2020 earnings.
- 4Research and Development (R&D) expenses increased by 1% to $760.7 million, representing 17.3% of net sales, with a focus on TMTT and TAVR programs.
- 5The COVID-19 pandemic impacted procedure volumes and clinical trial enrollments, though manufacturing and supply operations remained robust.
- 6Edwards Lifesciences ended 2020 with a strong liquidity position, holding $1.183 billion in cash and cash equivalents.
- 7The company's stock performance showed a cumulative total return of 346.53% from 2016 to 2020, outperforming the S&P 500 and S&P 500 Health Care Equipment indices.